US House of Representatives Approves $3.2 Billion for FDA Budget
The US House of Representatives approved of a $3.2 billion budget for the FDA for the 2021 fiscal year, a $40.8 million increase from the 2020 fiscal year. The additional funding is meant to support new initiatives for greater collaboration across departments within...
US Government to Pay Pharmaceutical Leader Pfizer and BioNTech Almost $2 Billion
The US government will pay American pharmaceutical leader Pfizer and German biotech BioNTech $1.95 billion USD to buy enough COVID-19 vaccines for approximately 50 million people. Pfizer and BioNTech will not receive payment until their...
Novartis Receives Approval For Asthma Medicine Enzair Breezhaler
The European Commission (EC) has granted approval for Novartis’ Enzair Breezhaler, a medicine for uncontrolled asthma. The drug therapy is utilized as a maintenance treatment for adults with asthma. “Novartis is working to reimagine medicine for people with...
US House Committee on Appropriation Approves Fiscal Year 2021 FDA Funding Bill
The US House Committee on Appropriation approved a $3.212 billion budget for the 2021 fiscal year. Part of the funding bill also gives the Food and Drug Administration authority to recall unsafe prescription and over-the-counter drugs. The proposed budget also...
United States Sets One-Day Record: Over 65,500 New Confirmed Cases of Covid
The United States on Thursday (7/10) reported across states, according to a Reuter’s tally, more than 60,500 new cases of Covid, setting the new record for the number of those confirmed to be infected in one day. As the cases are steadily on the rise in 41 out of the...
Covid Potential for Brain Damage, According to Scientists
A study conducted by researchers at University College London (UCL) reported 43 cases of patients diagnosed with Covid experiencing temporary brain damage. The scientists warned that new evidence suggests potential issues of severe neurological complications, like...
ABOUT US
CSOFT Health Sciences has over 15 years of experience providing end-to-end translation and localization solutions for all stages of the product life cycle, from pre-clinical to post-launch. We also specialize in China market access consulting services, Asian regulatory and eCTD submissions. Our operation is compliant with ISO 17100 and certified by BSI in ISO 9001:2015 and ISO 13485:2016, providing customized solutions to meet the rigorous regulatory requirements in global submission. For more information, please visit: www.csoftintl.com